Thursday, August 25, 2011 4:39:51 PM
FDA Approves Shire's Treatment For Swelling Disorder
11:14a ET August 25, 2011 (Dow Jones)
FDA Approves Shire's Treatment For Swelling Disorder
DOW JONES NEWSWIRES
Shire PLC's (SHPGY, SHP.LN) treatment for a rare swelling disorder was approved by the U.S. Food and Drug Administration.
The drug, Firazyr, is the third drug approved in the U.S. to treat attacks of a rare condition called hereditary angioedema, according to the FDA.
Firazyr is the first on-demand treatment for hereditary agiodema that patients can inject themselves when they feel an attack coming on, instead of seeking a health-care professional. This rare disorder is a potentially fatal condition that causes severe swelling in the hands and feet, gastrointestinal tract and upper airway.
The other FDA approved treatments are CSL Behring's Berinert to treat facial and abdominal attacks of the condition, and Dyax Corp.'s (DYAX) Kalbitor to treat acute attacks in patients ages 16 years and older.
-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM